Pharmaceutical Technology
JULY 28, 2022
The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants and intra-articular (IA) injections. Eli Lilly is another key player in the OA market due to duloxetine.
The Pharma Data
NOVEMBER 5, 2020
and Aavis Pharmaceuticals Inc. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. D/B/A Aavis Pharmaceuticals. About Jubilant Cadista Pharmaceuticals Inc. YARDLEY, Pa.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 26, 2021
Ex-US sales grew +3% (cc). Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines. Innovative Medicines net sales were USD 10.6
Pharmaceutical Technology
FEBRUARY 18, 2023
Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
The Pharma Data
MARCH 22, 2023
Sandoz has more than two decades of experience researching, developing and bringing biosimilars to markets across the globe. 2 When it launches, Hyrimoz HCF will represent the first launch of a Sandoz biosimilar in the US market in this specific disease space. Our ambition is to be the world’s leading and most valued generics company.
The Pharma Data
APRIL 4, 2023
With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. Source link: [link]
Pharmaceutical Technology
DECEMBER 22, 2022
Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising. The category includes any projects that demonstrate an innovative approach to the market.
Expert insights. Personalized for you.
130 
Let's personalize your content